0001209191-23-053269.txt : 20231020
0001209191-23-053269.hdr.sgml : 20231020
20231020164048
ACCESSION NUMBER: 0001209191-23-053269
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231019
FILED AS OF DATE: 20231020
DATE AS OF CHANGE: 20231020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jenkins Abigail L.
CENTRAL INDEX KEY: 0001947032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38716
FILM NUMBER: 231337516
MAIL ADDRESS:
STREET 1: C/O GAMIDA CELL LTD.
STREET 2: 116 HUNTINGTON AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gamida Cell Ltd.
CENTRAL INDEX KEY: 0001600847
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 NAHUM HAFZADI STREET
CITY: JERUSALEM
STATE: L3
ZIP: 95484
BUSINESS PHONE: 97226595666
MAIL ADDRESS:
STREET 1: 5 NAHUM HAFZADI STREET
CITY: JERUSALEM
STATE: L3
ZIP: 95484
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-19
0
0001600847
Gamida Cell Ltd.
GMDA
0001947032
Jenkins Abigail L.
C/O GAMIDA CELL LTD.
116 HUNTINGTON AVENUE
BOSTON
MA
02116
1
1
0
0
President and CEO
0
Ordinary Shares
2023-10-19
4
A
0
109013
0.00
A
375142
D
Employee Share Option (Right to Buy)
1.59
2023-10-19
4
A
0
217954
0.00
A
2033-10-18
Ordinary Shares
217954
217954
D
The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023.
Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.
33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date.
/s/ Joshua F. Patterson, Attorney-in-Fact
2023-10-20